Diagnostic Criteria, Treatment Evidence, and Mitochondrial Biology
1 Carruthers et al. 2011 — International Consensus Criteria (ICC)
Full Citation:: Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, Staines D, Powles ACP, Speight N, Vallings R, Bateman L, Bell DS, et al. Myalgic encephalomyelitis: International Consensus Criteria. Journal of Internal Medicine. 2011;270(4):327–338. DOI:: 10.1111/j.1365-2796.2011.02428.x PMID:: 21777306 Published:: October 2011 Study Design:: Expert consensus criteria development (26 co-authors; international) Key Findings::
- Introduced the most stringent widely-used ME/CFS diagnostic criteria, requiring: (1) post-exertional neuroimmune exhaustion as a cardinal feature, (2) neurological impairments (cognitive, pain, sensory, sleep), (3) immune/gastrointestinal/genitourinary impairments, and (4) energy production/transportation impairments
- More restrictive than Fukuda 1994 and Canadian Consensus Criteria 2003 (same lead author); explicitly excludes patients whose fatiguing illness is better explained by another condition
- Proposes the term “myalgic encephalomyelitis” (ME) as more accurate than “chronic fatigue syndrome”, reflecting documented neurological and immune findings
- Emphasises primary energy production impairment as a cardinal disease feature alongside post-exertional symptom exacerbationRelevance to ME/CFS:: Applied in the severity-stratified care chapter to ensure recommendations target confirmed ME rather than heterogeneous chronic fatigue. Distinct from the Canadian Consensus Criteria (CCC) 2003 and the IOM 2015 criteria. The emphasis on primary energy production impairment is directly relevant to the metabolic and mitochondrial dysfunction chapters. Certainty Assessment::
- *Quality:* High (Journal of Internal Medicine; 26 co-authors from leading international ME/CFS centres)
- *Study type:* Expert consensus; clinical criteria development; no prospective validation data
- *Limitations:* Consensus criteria without independent prospective validation; more restrictive than Fukuda 1994 (potentially excluding milder cases); ongoing debate about whether ME (ICC) and ME/CFS (IOM 2015) define the same population
- *Adoption:* Preferred for homogeneous research cohorts; used alongside IOM 2015 in many studies2 Wilshire et al. 2018 — Reanalysis of the PACE Trial
Full Citation:: Wilshire CE, Kindlon T, Courtney R, Matthees A, Tuller D, Geraghty K, Levin B. Rethinking the Treatment of Chronic Fatigue Syndrome—A Reanalysis and Evaluation of Findings from a Recent Major Trial of Graded Exercise and CBT. BMC Psychology. 2018;6(1):6. DOI:: 10.1186/s40359-018-0218-3 PMID:: 29562932 PMCID:: PMC5863477 Published:: March 2018 Study Design:: Methodological reanalysis of published trial data Key Findings::
- Reanalysis of the PACE trial (White et al.\ 2011; $n=641$; largest ME/CFS treatment trial to date) demonstrates that outcome thresholds were changed mid-trial in ways that substantially inflated apparent treatment response rates for GET and CBT
- Under original pre-specified primary outcomes, recovery rates for both treatments were dramatically lower than those reported in the primary publication
- Original published conclusions overestimated treatment benefit due to: (1) post-hoc threshold changes, (2) failure to use objective activity measures as primary outcomes, (3) overlap between “recovery” and “worsening” threshold definitions
- Objective actometer (step count) data showed no significant benefit of GET over standard medical careRelevance to ME/CFS:: Central evidence contributing to the removal of GET from ME/CFS management guidelines (NICE 2021). Relevant to the lifestyle interventions chapter and the argument that activity-based therapies can worsen ME/CFS by triggering post-exertional malaise in patients with abnormal physiological responses to exertion. Certainty Assessment::
- *Quality:* Medium-High (BMC Psychology; methodological critique with detailed statistical analysis)
- *Study type:* Secondary analysis / methodological critique; not a new empirical trial
- *Limitations:* Retrospective reanalysis; PACE investigators dispute the interpretation; ongoing debate about appropriate outcome measures for ME/CFS
- *Impact:* Directly contributed to NICE 2021 guideline revision removing GET; widely cited in ME/CFS policy contexts3 Lawless et al. 2015 — The Rise and Rise of Mitochondrial DNA Mutations
Full Citation:: Lawless C, Greaves L, Reeve AK, Turnbull DM, Vincent AE. The rise and rise of mitochondrial DNA mutations. Open Biology. 2015;5(5):150029. DOI:: 10.1098/rsob.150029 PMID:: 25979659 PMCID:: PMC4508218 Published:: May 2015 Study Design:: Review article Key Findings::
- Comprehensive mechanistic review of how mtDNA mutations accumulate through: (1) replication errors, (2) repair failures due to limited mtDNA repair machinery, (3) oxidative damage from proximity to the electron transport chain, (4) clonal expansion of mutated mitochondria
- mtDNA mutations accumulate non-linearly; once a mutant mtDNA exceeds a tissue-specific threshold (typically 60–80% heteroplasmy), mitochondrial function collapses
- Reactive oxygen species damage mtDNA approximately 10-fold more than nuclear DNA due to proximity to the electron transport chain and limited repair mechanisms
- Tissues with high energy demands (brain, muscle, heart) are most vulnerable to threshold-dependent functional collapseRelevance to ME/CFS:: Provides mechanistic basis for understanding cumulative mitochondrial dysfunction in ME/CFS. The oxidative stress-mtDNA damage pathway is consistent with the ME/CFS oxidative stress signature. The threshold effect explains why mitochondrial dysfunction might worsen progressively with disease duration. Relevant to explaining why repeated PEM episodes may have cumulative mitochondrial consequences exceeding what would be expected from simple acute oxidative stress. Certainty Assessment::
- *Quality:* Medium-High (Open Biology; Royal Society journal; Turnbull group are leading mitochondrial medicine researchers)
- *Study type:* Mechanistic review of well-established mitochondrial biology
- *Limitations:* Describes general mtDNA mutation biology; direct evidence for progressive mtDNA mutation accumulation as a consequence of ME/CFS crashes has not been established; cross-sectional studies show elevated mtDNA damage markers but not longitudinal accumulation5 Exercise Pathophysiology: Deconditioning Myth
Charlton et al. 2026 — PEM and the Myth of Cardiac Deconditioning
Full Citation:: Charlton BT, Janssen K, Systrom DM, Putrino D, W"ust RCI. Post-exertional malaise and the myth of cardiac deconditioning: rethinking the pathophysiology of long COVID. British Journal of Sports Medicine. 2026. Online ahead of print. DOI:: 10.1136/bjsports-2025-111387 PMID:: 41667155 Study Type:: Editorial/review
Key Arguments: Post-exertional malaise in long COVID cannot be explained by cardiac deconditioning. The authors—including Systrom (invasive CPET pioneer who demonstrated preload failure in ME/CFS) and Putrino (leading long COVID researcher at Mount Sinai)—argue that the pathophysiology of exercise intolerance in post-viral illness must be fundamentally reconsidered. Publication in a mainstream sports medicine journal signals growing acceptance within the exercise science community.
Relevance to ME/CFS: Directly supports the argument made throughout this document (Chapters Cardiovascular Dysfunction, Lifestyle and Non-Pharmacological Interventions, Deconditioning Hypothesis) that deconditioning is a secondary consequence of ME/CFS, not a primary cause. Provides a 2026 citation from within the sports medicine establishment challenging the exercise-as-treatment paradigm—complementing existing evidence from NICE guideline revision (2021), patient surveys, and two-day CPET studies.
Certainty Assessment:
- Quality: Medium (editorial, not original research; but authored by leading researchers with extensive primary data)
- Replication status: N/A (position paper synthesizing existing evidence)
- Clinical impact: High (challenges deconditioning narrative from within exercise science)
- Limitations: Editorial format; no new primary data; full text not yet available at time of integration
:::
Note: This bibliography was compiled in January 2025 and updated March 2026. The field of ME/CFS research is rapidly evolving, particularly with insights from Long COVID research. Readers are encouraged to search PubMed and preprint servers for the most current literature.